CDK4 and breast cancer: These findings collectively lay a robust experimental foundation, substantiating the clinical viability of a novel regimen comprising medium-dose neratinib, CDK4/6 inhibitor combined with endocrine therapy, offering an important avenue for optimizing treatment in HR+/HER2-low breast cancer.